57
Participants
Start Date
October 8, 2014
Primary Completion Date
November 5, 2019
Study Completion Date
November 5, 2019
Pazopanib
Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
Novartis Investigative Site, Budapest
Novartis Investigative Site, New York
Novartis Investigative Site, Norfolk
Novartis Investigative Site, Chapel Hill
Novartis Investigative Site, Madrid
Novartis Investigative Site, Charlotte
Novartis Investigative Site, Orlando
Novartis Investigative Site, St. Petersburg
Novartis Investigative Site, Nashville
Novartis Investigative Site, Cincinnati
Novartis Investigative Site, Indianapolis
Novartis Investigative Site, Minneapolis
Novartis Investigative Site, Chicago
Novartis Investigative Site, St Louis
Novartis Investigative Site, Kansas City
Novartis Investigative Site, Dallas
Novartis Investigative Site, Paris
Novartis Investigative Site, Fort Worth
Novartis Investigative Site, Houston
Novartis Investigative Site, Long Beach
Novartis Investigative Site, Orange
Novartis Investigative Site, Palo Alto
Novartis Investigative Site, Seattle
Novartis Investigative Site, Madera
Novartis Investigative Site, San Francisco
Novartis Investigative Site, Hartford
Novartis Investigative Site, Hackensack
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Prague
Novartis Investigative Site, Košice
Lead Sponsor
Children's Oncology Group
NETWORK
Novartis Pharmaceuticals
INDUSTRY